Genenta Science S.p.A.

Genenta Science S.p.A. (GNTA) priced its initial public offering on Dec 15, 2021 at $11.50 per ADS, raising $35.9M, and listed on Nasdaq Capital Market. At the IPO price its market capitalization was about $208.4M. Roth Capital was lead-left underwriter, joined by Maxim Group. Loeb & Loeb advised the company and Goodwin Procter advised the underwriters.

Genenta Science S.p.A. is a clinical-stage biotechnology company developing hematopoietic stem cell gene therapies for solid tumors. Its platform transfers a therapeutic gene into a patient's own stem cells so monocytes and macrophages deliver immunomodulatory molecules directly to the tumor.

Status

IPO

Ticker

GNTA

Exchange

Nasdaq Capital Market

Priced

Dec 15, 2021

IPO price

$11.50 per ADS

Raised

$35.9M

Market cap at IPO price

$208.4M

First filed

Nov 9, 2021

Underwriters

Roth Capital and Maxim Group

Company counsel

Loeb & Loeb

Underwriters' counsel

Goodwin Procter

Sector

Biotech & pharma

Country / state

Italy

Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.